Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dutasteride vs Testosterone (TRT): Testosterone (TRT) has the stronger overall evidence (5.6 vs 5.4/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Testosterone (TRT) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Dutasteride and Testosterone (TRT) have evidence — compare verdict strength side-by-side.
Approved BPH dose is 0.5 mg once daily; off-label hair-loss use mirrors the same 0.5 mg once-daily dose under a clinician. A prescription drug.
Any time of day
Oral soft-gel capsule (dutasteride 0.5 mg)
Prescription-only and clinician-directed — this is a controlled substance, NOT a self-administered supplement, and we do not provide a non-medical dosing protocol. For context only: TRT for diagnosed hypogonadism is titrated to a mid-normal testosterone level. Intramuscular testosterone esters (cypionate/enanthate) are commonly dosed around 50–100 mg weekly (or ~100–200 mg every 2 weeks); long-acting testosterone undecanoate is dosed less frequently. Transdermal gels (~50–100 mg/day applied) and subcutaneous injection are alternative routes. Supraphysiologic anabolic-steroid doses are far higher and dangerous — not a regimen this library endorses.
Any time of day
Clinician-prescribed testosterone (intramuscular ester or transdermal gel) for diagnosed hypogonadism — controlled substance, prescription-only
and 1 more not shown
3–6 months
Months
Years
Weeks; may persist
Weeks to months
Months
Months
Throughout use
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Journal of the American Academy of Dermatology (2006) · Rct · n=416
Randomized placebo-controlled trial of 416 men aged 21-45 comparing dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg and placebo daily for 24 weeks
Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.
Journal of the American Academy of Dermatology (2010) · Rct · n=153
Phase-III randomized double-blind placebo-controlled trial of 153 men over 6 months
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
European urology (2010) · Rct · n=4844
CombAT: 4-year multicenter randomized double-blind trial in 4,844 men aged 50 or over with symptomatic BPH and prostatic enlargement, comparing tamsulosin 0.4 mg, dutasteride 0.5 mg or both daily, with no placebo arm
Effects of Testosterone Treatment in Older Men.
The New England journal of medicine (2016) · Rct · n=790
The coordinated Testosterone Trials: 790 men aged 65 or older with testosterone below 275 ng/dl and symptoms, testosterone gel or placebo gel for one year, each man in one or more of the Sexual Function, Physical Function and Vitality Trials.
Cardiovascular Safety of Testosterone-Replacement Therapy.
The New England journal of medicine (2023) · Rct · n=5246
TRAVERSE: a randomized, double-blind, placebo-controlled noninferiority trial of daily 1.62% testosterone gel in 5,246 men aged 45 to 80 with hypogonadism and existing or high risk of cardiovascular disease, mean follow-up 33 months.
Safety and Efficacy of Testosterone Therapy on Musculoskeletal Health and Clinical Outcomes in Men: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Endocrine practice (2023) · Meta analysis · n=1728
Systematic review and meta-analysis of 16 randomized placebo-controlled trials (1,728 men, mean age 77) of testosterone therapy on bone, muscle, fat and strength.
Testosterone (TRT) has a higher evidence score (5.6/10 vs 5.4/10) and wins in 2 of 3 categories.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.